Potential role for HIV-specific CD38-/HLA-DR+ CD8+ T cells in viral suppression and cytotoxicity in HIV controllers

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Hua, Stéphane ^a,b   Lécuroux, Camille ^a,b   Sáez Cirión, Asier ^c   Pancino, Gianfranco ^c   Girault, Isabelle ^a,b   Versmisse, Pierre ^c   Boufassa, Faroudy ^b,d,e   Taulera, Olivier ^f   Sinet, Martine ^a,b   Lambotte, Olivier ^a,b,e   Venet, Alain ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT PASTEUR   (France)

^d CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^e BICÊTRE HOSPITAL   (France)

^f SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CD40 ANTIGEN; CD69 ANTIGEN; CD71 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; KI 67 ANTIGEN; PROTEIN BCL 2; LEUKOCYTE ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; VIRUS INHIBITION; ADULT; CASE CONTROL STUDY; CELL CULTURE; COMPARATIVE STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; VIROLOGY;

ADULT; ANTIGENS, CD; ANTIGENS, CD38; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84904396633     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101920     Document Type: Article

References (48)

1. Deeks SG, Walker BD (2007) Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27: 406-416. doi:10.1016/j.immuni.2007.08.010. (Pubitemid 47418678)
2. Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, et al. (2005) HIV Controllers: A Homogeneous Group of HIV-1 - Infected Patients with Spontaneous Control of Viral Replication. Clin Infect Dis 41: 1053-1056. doi:10.1086/433188. (Pubitemid 41368233)
3. Sáez-Cirión A, Pancino G (2013) HIV controllers: a genetically determined or inducible phenotype? Immunol Rev 254: 281-294. doi:10.1111/imr.12076.
4. Carrington M, O'Brien SJ (2003) The influence of HLA genotype on AIDS. Annu Rev Med 54: 535-551. doi:10.1146/annurev.med.54.101601.152346. (Pubitemid 37386411)
5. Carrington M, Walker BD (2012) Immunogenetics of spontaneous control of HIV. Annu Rev Med 63: 131-145. doi:10.1146/annurev-med-062909-130018.
6. Goulder PJR, Walker BD (2012) HIV and HLA class I: an evolving relationship. Immunity 37: 426-440. doi:10.1016/j.immuni.2012.09.005.
7. Loffredo JT, Maxwell J, Qi Y, Glidden CE, Borchardt GJ, et al. (2007) Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol 81: 8827-8832. doi:10.1128/JVI.00895-07. (Pubitemid 47242856)
8. Yant LJ, Friedrich TC, Johnson RC, May GE, Maness NJ, et al. (2006) The High-Frequency Major Histocompatibility Complex Class I Allele Mamu-B*17 Is Associated with Control of Simian Immunodeficiency Virus SIVmac239 Replication. J Virol 80: 5074-5077. doi:10.1128/JVI.80.10.5074-5077.2006.
9. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789. doi:10.1182/blood-2005-12-4818. (Pubitemid 43882629)
10. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, et al. (2002) HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 3: 1061-1068. doi:10.1038/ni845. (Pubitemid 35363659)
11. Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, et al. (2008) Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29: 1009-1021. doi:10.1016/j.immuni.2008.10.010.
12. Chen H, Piechocka-Trocha A, Miura T, Brockman MA, Julg BD, et al. (2009) Differential Neutralization of Human Immunodeficiency Virus (HIV) Replication in Autologous CD4 T Cells by HIV-Specific Cytotoxic T Lymphocytes. J Virol 83: 3138-3149. doi:10.1128/JVI.02073-08.
13. Sáez-Cirión A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, et al. (2007) HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 104: 6776-6781. doi:10.1073/pnas.0611244104. (Pubitemid 47175577)
14. Doisne J-M, Urrutia A, Lacabaratz-Porret C, Goujard C, Meyer L, et al. (2004) CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol Baltim Md 1950 173: 2410-2418. (Pubitemid 39063097)
15. Sáez-Cirión A, Sinet M, Shin SY, Urrutia A, Versmisse P, et al. (2009) Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol Baltim Md 1950 182: 7828-7837. doi:10.4049/jimmunol.0803928.
16. Kaech SM, Wherry EJ, Ahmed R (2002) Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2: 251-262. doi:10.1038/nri778. (Pubitemid 37323225)
17. Sachdeva M, Fischl MA, Pahwa R, Sachdeva N, Pahwa S (2010) Immune Exhaustion Occurs Concomitantly With Immune Activation and Decrease in Regulatory T Cells in Viremic Chronically HIV-1-Infected Patients: JAIDS J Acquir Immune Defic Syndr54: 447-454. doi:10.1097/QAI.0b013e3181e0c7d0.
18. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, et al. (2006) Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 12: 1198-1202. doi:10.1038/nm1482. (Pubitemid 44527357)
19. Deeks SG, Kitchen CMR, Liu L, Guo H, Gascon R, et al. (2004) Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104: 942-947. doi:10.1182/blood-2003- 09-3333. (Pubitemid 39038012)
20. Sáez-Cirión A, Shin SY, Versmisse P, Barré-Sinoussi F, Pancino G (2010) Ex vivo T cell-based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses. Nat Protoc 5: 1033-1041. doi:10.1038/nprot.2010.73.
21. Lécuroux C, Sáez-Cirión A, Girault I, Versmisse P, Boufassa F, et al. (2014) Both HLA-B*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers. J Virol 88: 176-187. doi:10.1128/JVI.02098-13.
22. Manion M, Rodriguez B, Medvik K, Hardy G, Harding CV, et al. (2012) Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PloS One 7: e30306. doi:10.1371/journal.pone.0030306.
23. Hervas-Stubbs S, Riezu-Boj J-I, Gonzalez I, Mancheño U, Dubrot J, et al. (2010) Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8(+) T cells. Eur J Immunol 40: 3389-3402. doi:10.1002/eji.201040664.
24. Bourgeois C, Rocha B, Tanchot C (2002) A Role for CD40 Expression on CD8+ T Cells in the Generation of CD8+ T Cell Memory. Science 297: 2060-2063. doi:10.1126/science.1072615.
25. Caruso A, Licenziati S, Corulli M, Canaris A, De Francesco M, et al. (1997) Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry 27: 71-76. doi:10.1002/(SICI)1097-0320(19970101)27:1〈71::AID-CYTO9〉3.0.CO;2-O. (Pubitemid 27059784)
26. Speiser DE, Migliaccio M, Pittet MJ, Valmori D, Liénard D, et al. (2001) Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells. Eur J Immunol 31: 459-466. doi:10.1002/1521-4141(200102)31:2&60;459::AID.
27. Imamichi H, Lempicki RA, Adelsberger JW, Hasley RB, Rosenberg A, et al. (2012) The CD8+ HLA-DR+ T cells expanded in HIV-1 infection are qualitatively identical to those from healthy controls. Eur J Immunol 42: 2608-2620. doi:10.1002/eji.201142046.
28. Buckheit RW III, Salgado M, Silciano RF, Blankson JN (2012) Inhibitory potential of subpopulations of CD8+ T cells in HIV-1-infected elite suppressors. J Virol 86: 13679-13688. doi:10.1128/JVI.02439-12.
29. Sandoval-Montes C, Santos-Argumedo L (2005) CD38 is expressed selectively during the activation of a subset of mature T cells with reduced proliferation but improved potential to produce cytokines. J Leukoc Biol 77: 513-521. doi:10.1189/jlb.0404262. (Pubitemid 40489527)
30. Ndhlovu ZM, Proudfoot J, Cesa K, Alvino DM, McMullen A, et al. (2012) Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses. J Virol 86: 6959-6969. doi:10.1128/JVI.00531-12.
31. Campillo-Gimenez L, Laforge M, Fay M, Brussel A, Cumont M-C, et al. (2010) Nonpathogenesis of simian immunodeficiency virus infection is associated with reduced inflammation and recruitment of plasmacytoid dendritic cells to lymph nodes, not to lack of an interferon type I response, during the acute phase. J Virol 84: 1838-1846. doi:10.1128/JVI.01496-09.
32. Barblu L, Machmach K, Gras C, Delfraissy J-F, Boufassa F, et al. (2012) Plasmacytoid dendritic cells (pDCs) from HIV controllers produce interferon-α and differentiate into functional killer pDCs under HIV activation. J Infect Dis 206: 790-801. doi:10.1093/infdis/jis384.
33. Herbeuval J-P, Shearer GM (2007) HIV-1 immunopathogenesis: How good interferon turns bad. Clin Immunol 123: 121-128. doi:10.1016/j.clim.2006.09.016. (Pubitemid 46590066)
34. Herbeuval J-P, Nilsson J, Boasso A, Hardy AW, Kruhlak MJ, et al. (2006) Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc Natl Acad Sci U S A 103: 7000-7005. doi:10.1073/pnas.0600363103.
35. West EE, Youngblood B, Tan WG, Jin H-T, Araki K, et al. (2011) Tight regulation of memory CD8(+) T cells limits their effectiveness during sustained high viral load. Immunity 35: 285-298. doi:10.1016/j.immuni.2011.05.017.
36. Betts MR, Price DA, Brenchley JM, Loré K, Guenaga FJ, et al. (2004) The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol Baltim Md 1950 172: 6407-6417. (Pubitemid 38621250)
37. Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, et al. (2008) Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med 14: 1390-1395. doi:10.1038/nm.1779.
38. Almeida JR, Sauce D, Price DA, Papagno L, Shin SY, et al. (2009) Antigen sensitivity is a major determinant of CD8 + T-cell polyfunctionality and HIV-suppressive activity. Blood 113: 6351-6360. doi:10.1182/blood-2009-02- 206557.
39. Berger CT, Frahm N, Price DA, Mothe B, Ghebremichael M, et al. (2011) High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. J Virol 85: 9334-9345. doi:10.1128/JVI.00460-11.
40. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, et al. (2007) Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204: 2473-2485. doi:10.1084/jem.20070784. (Pubitemid 47529331)
41. Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, et al. (2010) Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 6: e1000917. doi:10.1371/journal.ppat.1000917.
42. Giorgi JV, Lyles RH, Matud JL, Yamashita TE, Mellors JW, et al. (2002) Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 1999 29: 346-355. (Pubitemid 34288887)
43. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, et al. (2008) Relationship between T cell activation and CD4 + T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 197: 126-133. doi:10.1086/524143. (Pubitemid 351263476)
44. Pereyra F, Palmer S, Miura T, Block BL, Wiegand A, et al. (2009) Persistent Low-Level Viremia in HIV-1 Elite Controllers and Relationship to Immunologic Parameters. J Infect Dis 200: 984-990. doi:10.1086/605446.
45. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371. doi:10.1038/nm1511. (Pubitemid 44924494)
46. Boufassa F, Saez-Cirion A, Lechenadec J, Zucman D, Avettand-Fenoel V, et al. (2011) CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory. PloS One 6: e18726. doi:10.1371/journal.pone. 0018726.
47. Okulicz JF, Marconi VC, Landrum ML, Wegner S, Weintrob A, et al. (2009) Clinical Outcomes of Elite Controllers, Viremic Controllers, and Long-Term Nonprogressors in the US Department of Defense HIV Natural History Study. J Infect Dis 200: 1714-1723. doi:10.1086/646609.
48. Giorgi JV, Ho HN, Hirji K, Chou CC, Hultin LE, et al. (1994) CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group. J Infect Dis 170: 775-781.